First Turn Management LLC Takes $7.70 Million Position in uniQure N.V. $QURE

First Turn Management LLC purchased a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 321,655 shares of the biotechnology company’s stock, valued at approximately $7,697,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Woodline Partners LP boosted its holdings in uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares in the last quarter. Legal & General Group Plc bought a new stake in uniQure in the second quarter worth $497,000. Marshall Wace LLP boosted its holdings in uniQure by 276.5% in the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after purchasing an additional 163,749 shares in the last quarter. California State Teachers Retirement System bought a new stake in uniQure in the second quarter worth $540,000. Finally, Ameriprise Financial Inc. boosted its holdings in uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after purchasing an additional 212,218 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Wall Street Analysts Forecast Growth

QURE has been the subject of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a report on Tuesday, May 5th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. HC Wainwright decreased their price objective on shares of uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $12.00 to $35.00 in a report on Wednesday, March 11th. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

uniQure Stock Up 2.8%

QURE stock opened at $27.57 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The company has a 50-day moving average of $22.52 and a two-hundred day moving average of $21.80. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. As a group, equities research analysts anticipate that uniQure N.V. will post -3.64 EPS for the current year.

Insider Activity at uniQure

In other uniQure news, Director Madhavan Balachandran sold 1,993 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the sale, the director directly owned 43,254 shares in the company, valued at $1,170,453.24. This represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leonard E. Post sold 1,993 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the sale, the director owned 35,494 shares of the company’s stock, valued at $960,467.64. This trade represents a 5.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 85,817 shares of company stock valued at $2,232,383. 4.65% of the stock is owned by corporate insiders.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.